CD8+ T细胞从功能正常到 ... 他们开发了一种名为CAR增强剂（CAR-E）的新型治疗平台，旨在提升CAR-T细胞的活性和持久性，从而避免癌症复发。

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

The study, published today in the journal Nature Immunology, focused on chimeric antigen receptor (CAR)-T cells, an effective therapy against ... functional states of CD8+ CAR T cells during ...

Chimeric antigen receptor (CAR) T cell therapy is an immunotherapy. It uses a patient’s own immune system to fight certain blood cancers. Normal T cells can “hook” onto cancer cells and kill them, but ...

CAR-T cell therapy involves extracting a patient’s T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body.

A new study from researchers at the University of Leipzig Medical Center and collaborators, has discovered a rare but serious side effect of an innovative form of blood cancer therapy in a 63-year-old ...

The company's lead asset, cema-cel, aims to shift CAR-T therapy to early intervention, potentially expanding its market and redefining treatment standards. ALLO-329 targets autoimmune diseases ...

Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease ...

Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma. Various factors play a role in whether or not a patient is ...